Description

Retatrutide represents an advanced synthetic peptide engineered as a triple agonist with activity at glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This multi-target approach allows for investigation of complex metabolic signaling networks and their integrated effects on glucose homeostasis, energy expenditure, and metabolic regulation. The compound incorporates structural modifications designed to achieve balanced activity across all three receptor systems while maintaining stability and bioavailability for research applications. The triple receptor activity profile provides unique opportunities for investigating the combined effects of incretin and glucagon signaling pathways in comprehensive metabolic regulation studies. Research applications include examination of multi-receptor metabolic signaling, energy homeostasis mechanisms, and advanced metabolic pathway interactions. For research use only.